Your browser doesn't support javascript.
loading
Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
Camorani, Simona; Crescenzi, Elvira; Fedele, Monica; Cerchia, Laura.
Affiliation
  • Camorani S; Consiglio Nazionale delle Ricerche, Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore" (IEOS), Via S. Pansini 5, 80131 Naples, Italy.
  • Crescenzi E; Consiglio Nazionale delle Ricerche, Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore" (IEOS), Via S. Pansini 5, 80131 Naples, Italy.
  • Fedele M; Consiglio Nazionale delle Ricerche, Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore" (IEOS), Via S. Pansini 5, 80131 Naples, Italy.
  • Cerchia L; Consiglio Nazionale delle Ricerche, Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore" (IEOS), Via S. Pansini 5, 80131 Naples, Italy. Electronic address: cerchia@unina.it.
Biochim Biophys Acta Rev Cancer ; 1869(2): 263-277, 2018 Apr.
Article in En | MEDLINE | ID: mdl-29574128
ABSTRACT
Transmembrane receptor tyrosine kinases (RTKs) play crucial roles in cancer cell proliferation, survival, migration and differentiation. Area of intense research is searching for effective anticancer therapies targeting these receptors and, to date, several monoclonal antibodies and small-molecule tyrosine kinase inhibitors have entered the clinic. However, some of these drugs show limited efficacy and give rise to acquired resistance. Emerging highly selective compounds for anticancer therapy are oligonucleotide aptamers that interact with their targets by recognizing a specific three-dimensional structure. Because of their nucleic acid nature, the rational design of advanced strategies to manipulate aptamers for both diagnostic and therapeutic applications is greatly simplified over antibodies. In this manuscript, we will provide a comprehensive overview of oligonucleotide aptamers as next generation strategies to efficiently target RTKs in human cancers.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Drug Design / Receptor Protein-Tyrosine Kinases / Protein Kinase Inhibitors / Aptamers, Nucleotide / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Year: 2018 Type: Article

Full text: 1 Database: MEDLINE Main subject: Drug Design / Receptor Protein-Tyrosine Kinases / Protein Kinase Inhibitors / Aptamers, Nucleotide / Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Year: 2018 Type: Article